Navigation Links
Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Date:2/23/2011

ive diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs as well as all aspects of antisense drug discovery, development and manufacturing.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis Pharmaceuticals and the discovery, development and potential of ISIS-CRPRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- CVS Health (NYSE: CVS ) announced today ... regional health systems to enhance access to high-quality, affordable health ... Health System in Alabama ; Community Health ... Pennsylvania , Northwest Medical Center, including Oro Valley ... in Tennessee ; and Premier Health in ...
(Date:10/30/2014)...  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced an upcoming presentation highlighting its ... The presentation, titled, "Drug Conjugates Bind Covalently to ... Sant P. Chawla , M.D., F.R.A.C.P., Director ... of the Company,s ongoing global, pivotal Phase 3 ...
(Date:10/30/2014)... Oct. 30, 2014 Today, DripDrop, the ... that it was awarded a two-year contract, effective ... company that serves the more than 100,000 members ... Association and Provista.  DripDrop also ... from member hospitals who attended the recent Novation ...
Breaking Medicine Technology:CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4
... ,, LAIYANG, China , July 9 /PRNewswire-Asia-FirstCall/ -- ... present at the Global Hunter Securities,China Investment Conference, which takes place July 11-13, 2010 ... , , ... 2010 , , , ...
... July 8 Sysmex, a global leader ... technology, today announced a three-year, dual source urinalysis ... purchasing/leasing access to Sysmex automated urine particle analyzers, ... for Amerinet members will be provided through Sysmex ...
Cached Medicine Technology:Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference 2Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference 3Sysmex America Announces Amerinet Urinalysis Contract 2Sysmex America Announces Amerinet Urinalysis Contract 3
(Date:10/30/2014)... 2014 Horse Sense & Sensitivity ... to special needs individuals in the Jacksonville area, will ... 15 from 10-2:00 p.m. at Bailey's Farm (2202 Bishop ... the public and is designed to raise awareness and ... the HSS Round-Up is free. Ticket purchases will be ...
(Date:10/30/2014)... The annual meeting of The North ... on Saturday, October 18th, marking the end of the ... NAMS is North America’s leading non-profit organization dedicated to ... women during midlife and beyond through an understanding of ... thought leaders from fields as varied as gynecology, sociology, ...
(Date:10/30/2014)... Amy Norton HealthDay ... Exposure to a common plastics, chemical during pregnancy may have ... hints. Researchers found that baby boys born to moms ... have a shorter anogenital distance -- the space between the ... and it,s considered a marker of exposure to androgens ("male" ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- A new ... life-threatening meningococcal disease was approved by the U.S. Food ... to protect people between the ages of 10 and ... meningitidis serogroup B bacteria. The bacteria can ... the spinal cord and brain. It is a leading ...
(Date:10/29/2014)... cancer medications are linked with an increased risk of ... failure or prior heart attacks. Published in BJU ... weigh the benefits and risks of the drugs. ... male hormones in the body to prevent them from ... prostate cancer. Despite its anticancer effects, ADT has been ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2
... released important information about epilepsy and seizure,disorders to dispel ... Edward Kennedy (D-Mass)., Senator Kennedy, 76, one of ... a seizure on Saturday. A seizure is a,disturbance in ... Americans,will have a single seizure at some point in ...
... foods, such as bread, pasta, often goes unnoticed , , ... lead to improved diagnosis and treatment of celiac disease, ... meeting in San Diego. , Celiac disease, which ... an autoimmune disorder in the small intestine triggered by ...
... developing reliable genetic tests to guide lung cancer treatment ... recently evaluated the ability of five high-risk genetic profiles, ... recur in patients whose non-small cell lung cancer was ... findings at the American Thoracic Societys 2008 International Conference ...
... 19 Roche Diagnostics today announced,that Quest Diagnostics ... of,diagnostic testing, information and services, has signed a ... TaqMan(R) HIV-1 Test for,HIV viral load testing., ... effects of,antiretroviral therapy by measuring changes in HIV-1 ...
... Risks and Identifies ... Approaches to Manage Those Risks, SCHAUMBURG, Ill., May 19 ... of gas, inflation is affecting every,American. Among the largest groups affected ... current retirees who are experiencing,soaring costs in a volatile economy., ...
... 19 On May 13, 2008, the Cancer,Prevention Coalition, ... FDA. This updates scientific information detailed in a,November 17, ... It also,documents prior knowledge of the FDA and industry ... basis of the 2008 Petition is detailed in 11 ...
Cached Medicine News:Health News:The Epilepsy Foundation Sheds Light on Seizures 2Health News:Advances Aid Treatment, Diagnosis of Celiac Disease 2Health News:Advances Aid Treatment, Diagnosis of Celiac Disease 3Health News:Will lung cancer recur? A genetic test may provide the answer 2Health News:Quest Diagnostics Chooses Roche's Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide 2Health News:Inflation Ranks as Today's Top Retirement Concern 2Health News:Inflation Ranks as Today's Top Retirement Concern 3Health News:Inflation Ranks as Today's Top Retirement Concern 4Health News:Petition Seeking a Cancer Warning on Cosmetic Talc Powder Products 2
IMMCO ANA Elisa meets the guidelines for the laboratory diagnosis and monitoring of systemic autoimmune rheumatic diseases intended for the use of clinical pathologists and laboratory physicians....
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
Medicine Products: